Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VBI Vaccines (VBIV)

VBI Vaccines Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VBIV
DateTimeSourceHeadlineSymbolCompany
16/04/202413:00Business WireVBI Vaccines Reports Full Year 2023 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
11/04/202421:05Business WireVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:VBIVVBI Vaccines Inc
09/04/202419:45Business WireVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:VBIVVBI Vaccines Inc
03/04/202413:00Business WireVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaNASDAQ:VBIVVBI Vaccines Inc
02/04/202413:00Business WireVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformNASDAQ:VBIVVBI Vaccines Inc
14/02/202413:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
14/02/202412:00Business WireVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesNASDAQ:VBIVVBI Vaccines Inc
06/02/202421:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
23/01/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
11/01/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
12/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
29/11/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
20/11/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
20/11/202313:00Business WireVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNASDAQ:VBIVVBI Vaccines Inc
14/11/202321:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
14/11/202321:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VBIVVBI Vaccines Inc
14/11/202321:05Business WireVBI Vaccines Reports Third Quarter 2023 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
03/11/202321:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/10/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/10/202313:00Business WireVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramNASDAQ:VBIVVBI Vaccines Inc
27/09/202312:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
27/09/202312:30Business WireVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernNASDAQ:VBIVVBI Vaccines Inc
07/09/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
07/09/202313:00Business WireVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMNASDAQ:VBIVVBI Vaccines Inc
06/09/202314:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
06/09/202313:00Business WireVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BNASDAQ:VBIVVBI Vaccines Inc
14/08/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VBIVVBI Vaccines Inc
14/08/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
14/08/202313:00Business WireVBI Vaccines Reports Second Quarter 2023 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
 Showing the most relevant articles for your search:NASDAQ:VBIV